2022 AMI Online Salon

XL102 An investigational CDK7 inhibitor for solid tumors

Project Detail

  • Entrant Name:  Sonya Amin
  • Client: Exelixis
  • Copyright: Exelixis, Inc., 2021
  • Medium/software used: Autodesk Maya, Redshift, Adobe AfterEffects, Phtotoshop and Illustrator
  • Final presentation format: HD video
  • Primary Audience: Healthcare providers (HCPs)

Project Description

The multifunctional enzyme CDK7 is overexpressed in a wide range of tumor types. As a key regulator of both cell cycle and transcription, it has emerged as a promising target for investigational cancer therapies; however, no CDK7-targeted therapies have been approved for clinical use to date. Our client wanted a video to educate HCPs on the rationale for targeting CDK7 in cancer and the mechanism of action of their novel CDK7 inhibitor that had just entered clinical trials. We used a recurring Venn diagram motif throughout the piece to reinforce the unique dual role of CDK7 in cell cycle progression and transcription. Since CDK7 mediates its dual function through large, multi-protein complexes, we used multiple data to build and animate these complexes, including the 50-subunit RNAPII pre-initiation complex. Using motion graphics and contrasting cool and warm color palettes, we established a visual language to easily differentiate between the normal and malignant activities of CDK7.